Continuing Pharmacy Education / CE Master List / Antipsychotic Utilization in a Pediatric Population-RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Antipsychotic Utilization in a Pediatric Population-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

1. Describe current practice guidelines regarding the use of antipsychotic medications in a pediatric population.
2.  Outline adverse effects associated with the use of antipsychotic medication in a pediatric population.
3.  Discuss when to initiate an antipsychotic medication in a pediatric patient.

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-043-H01-P

Session Code

23RW43-XYW84

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-043-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Megan J. Ehret PharmD, MS, BCPP
Professor, Co-Director of Mental Health Program
University of Maryland School of Pharmacy
Baltimore, MD

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Ehret is a consultant with Saladex Biomedical

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Post Test

Antipsychotic Utilization in a Pediatric Population

Megan Ehret, PharmD

 
1. Which medication is a first-line treatment option for a 14-year-old patient with newly diagnosed schizophrenia?
a. Divalproex Sodium
b. Haloperidol
C. Risperidone

2. Which medication is a first-line treatment option for a 16-year-old patient with bipolar disorder, most recent episode depressed?
A. Aripiprazole
B. Divalproex Sodium
C. Lurasidone

3. Which medication can cause the most substantial weight gain?
A. Cariprazine
B. Lumateperone
C. Olanzapine

4. Which rating scale should be used to screen patients for tardive dyskinesia?

A. Extrapyramidal Symptom Rating Scale
B. Barnes Akathisia Rating Scale
C. Abnormal Involuntary Movement Scale

5. In which disease state would it be appropriate to initiate an antipsychotic medication in a pediatric patient?
A. Autism
B. Conduct Disorder
C. Intellectual Disability

Handouts

Download

VIDEO